No Data
No Data
Innovative Healthcare (002173.SZ): Net loss of 2,977,900 yuan in the first quarter
On April 26, Ge Longhui | Innovative Healthcare (002173.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 201 million yuan, down 1.40 from the previous year; net profit attributable to shareholders of listed companies - RMB 2,977,900; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses - RMB 2.7087 million; and basic earnings per share - 0.0067 yuan.
Xinyi Biotech recently announced that it has received an investment of 100 million yuan from the Beijing Pharmaceutical Fund. Xinyi Biotech's current support from the Beijing Pharmaceutical Fund will accelerate the company's clinical registration of digit
Xinyi Biotech recently announced that it has received an investment of 100 million yuan from the Beijing Pharmaceutical Fund. Xinyi Biotech's current support from the Beijing Pharmaceutical Fund will accelerate the company's clinical registration of digital PCR and molecular POCT series reagent products. According to information, the Beijing Medical and Health Industry Investment Fund is a government investment fund in the medical and health industry established by Beijing at the end of 2023 that focuses on key industries such as innovative drugs and innovative medical devices, as well as emerging industries such as cell and gene therapy and digital medicine.
Express News | Beijing: Support the establishment of a training center for the application of innovative devices such as medical robots to accelerate the promotion and use of innovative medical devices
Innovative Healthcare (002173.SZ): Net loss of 34.2877 million yuan in 2023
On April 12, Ge Longhui (002173.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 806 million yuan, an increase of 13.51% over the previous year; net profit attributable to shareholders of listed companies was -34,287,700 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -280.26 million yuan; and basic earnings per share -0.08 yuan.
Express News | West China Hospital of Sichuan University signed a strategic cooperation framework agreement with iFLY Healthcare and Huawei to focus on the field of hospital artificial intelligence
Sanxin Medical (300453.SZ): The products of the holding subsidiary passed the innovative medical device review
Sanxin Medical (300453.SZ) announced that recently, Jiangxi Colectin Biotechnology Co., Ltd. (hereinafter referred to as “colevipid”), a holding subsidiary of the company, received the “Jiangxi Province Class II Medical Device Innovative Product Registration Review Results Form” issued by the Jiangxi Drug Administration. The “Leakage Monitor”, a product independently developed by Colectin, was approved for the registration review of Class II medical device innovation products in Jiangxi Province.
No Data